Skip to main content

Table 1 Patient demographics and baseline disease characteristics

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Parameters

n = 15

Gender (female/male)

13/2

Age (years)

49 (33–73)

Median years post-diagnosis

2.9 (1–16)

Ocular symptoms

15 (100%)

Schirmer-I test (mm)

12 ± 12

Oral symptoms

15 (100%)

Unstimulated salivary flow (ml/minute)

0.07 ± 0.13

Moderate-to-severe fatigue

13 (87%)

Fatigue VAS (mm)

56 ± 22

Focus score ≥ 1

12 (80%)

Anti-Ro antibodies

12 (80%)

Anti-La antibodies

11 (73%)

ESR (mm/hour)

33 ± 15

IgG (mg/dl)

2,114 ± 934

  1. ESR, erythrocyte sedimentation rate; Ig, immunoglobulin; VAS, visual analogue scale.